Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viemed Healthcare (VMD) Depreciation & Amortization (CF) (2018 - 2025)

Viemed Healthcare (VMD) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 18.91% year-over-year to $7.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 12.79%, and an annual FY2025 reading of $28.6 million, up 12.79% over the prior year.
  • Depreciation & Amortization (CF) was $7.6 million for Q4 2025 at Viemed Healthcare, roughly flat from $7.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $7.6 million in Q4 2025 and bottomed at $2.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $5.1 million, with a median of $5.6 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) surged 44.99% in 2023, then rose 5.22% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $3.1 million in 2021, then soared by 40.16% to $4.4 million in 2022, then surged by 35.35% to $5.9 million in 2023, then increased by 7.55% to $6.4 million in 2024, then grew by 18.91% to $7.6 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VMD at $7.6 million in Q4 2025, $7.5 million in Q3 2025, and $6.9 million in Q2 2025.